German-based CRO Verum Opens US Office for Clinical Services in Eastern/Central Europe
Verum.de
(Verum), a full-clinical service, German-based contract research organization (CRO) with experience in Central and Eastern European countries (CEE), has opened a new office in Carlsbad, Calif. The company opened the office to make its
clinical trial services
more readily available to clients in the U.S. and North America. By conducting clinical trials with Verum in CEE countries, clients will benefit from faster patient enrollment, more affordable trials, and the ease of working with a CRO with regional expertise that practices Western standards for clinical trials and bridges cultural differences.
Kristi Clark will be managing the new U.S. office, in charge of day-to-day operations, new business acquisition, project management and marketing. Clark has experience in global project management and more than 20 years of pharma industry experience, having worked at both large and mid-size CROs, including Quintiles, Parexel and Synteract. Her prior experience included a nearly two year stay in the Czech Republic opening an office in Prague.
Verum, experienced in working with American pharma and biotech companies and as a sub-contractor to CROs not present in the CEE region, recently ran a U.S. government-sponsored trial and has received commendations for the high quality of its data from Columbia University. Verum can also assist with registering drugs for commercial use in CEE countries and provides full logistic service, something other CROs often cannot do. Verum has more than 100 office based employees operating out of eight locations, including its
Munich headquarters
, and everyone speaks English. Clients are also afforded the choice between U.S. or German based contracts. The company offers therapeutic specialties in cardiovascular, neurology, psychiatry, CNS, oncology and pain, among others.
“I founded this company on Western principles and our longevity is proof of our hard-work, diligence and attention to detail,” explained Christian Sacher, Verum CEO. “We are well-versed in running trials in Central and Eastern European and former Soviet bloc countries because in many cases we were the first to do so; our goal is to bring more client trials to CEE countries so they can see the
difference
faster enrollment and regional expertise provides.”
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
